Osoresnontrine

Overview

Osoresnontrine is under investigation in clinical trial NCT02281773 (A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine	2020/10/26	NCT04602221	Phase 1	Completed	Boehringer Ingelheim
This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study)	2019/05/01	NCT03934203	Phase 1	Completed	Boehringer Ingelheim
This Study in Healthy Men and Women Tests How the Body Takes up BI 409306	2018/04/23	NCT03505151	Phase 1	Completed	Boehringer Ingelheim
This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months	2017/11/22	NCT03351244	Phase 2	Terminated	Boehringer Ingelheim
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year	2017/07/26	NCT03230097	Phase 2	Terminated	Boehringer Ingelheim
This Study Tests in Healthy Korean Women Which Effects BI 409306 and a Birth-control Pill Have on Each Other	2017/06/20	NCT03193307	Phase 1	Completed	Boehringer Ingelheim
Drug-drug Interaction Trial Between Rifampicin and BI 409306 in Healthy Volunteers	2017/05/12	NCT03151499	Phase 1	Completed	Boehringer Ingelheim
Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female Subjects	2015/12/21	NCT02635750	Phase 1	Completed	Boehringer Ingelheim
BI 409306 Cardiac Safety Trial in Healthy Volunteers	2015/05/08	NCT02438683	Phase 1	Completed	Boehringer Ingelheim
BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.	2015/01/14	NCT02337907	Phase 2	Completed	Boehringer Ingelheim

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

AI-Powered Research

Premium Access